NAD Precursors REMS Programs and Handling: What Every Woman Needs to Know

What Is a REMS, and Do NAD Precursors Have One?

A Risk Evaluation and Mitigation Strategy is an FDA-mandated safety program that applies to approved prescription drugs whose benefits outweigh risks only when specific precautions are followed. As of early 2025, no NAD precursor sold in the United States carries a REMS designation, because none has completed the FDA drug-approval pathway. The FDA's REMS database lists approved REMS programs; NAD precursors are absent.

That absence is not a green light. It reflects their current legal status as dietary supplements or, in the case of NMN, a contested regulatory category, not a judgment that they are proven safe at any dose or in any population.

How FDA Classifies NMN and NR Right Now

The FDA issued a proposed rule in late 2022 indicating that NMN was excluded from the definition of a dietary supplement because it had been studied as a drug before being marketed as a supplement. This proposed rule has created a grey zone in which NMN products remain available but legally questionable. NR, by contrast, has received New Dietary Ingredient notifications and currently occupies more stable supplement territory.

For women purchasing either compound, this regulatory instability matters. No mandatory label warnings, no pharmacist counseling requirement, and no restricted-distribution network currently exist.

What a Future REMS Could Look Like

If any NAD precursor progressed through an NDA as a prescription drug, a REMS could theoretically require:

• Prescriber enrollment and certification
• Pregnancy testing before dispensing (as seen with teratogenic drugs such as isotretinoin under iPLEDG)
• A Medication Guide distributed at every dispensing
• Restricted pharmacy or specialty-distributor networks

None of these requirements exist today. Women should treat that fact as a reason for caution, not a reason for confidence.

Sex-Specific Physiology: Why NAD Metabolism Differs in Women

NAD+ is not static across a woman's life. Understanding why requires a short look at the biology.

The Estrogen-NAD Connection

Estrogen biosynthesis and NAD+ metabolism share enzymatic territory. PARP enzymes, which consume NAD+ during DNA repair, are modulated by estradiol signaling. A 2021 review in Aging Cell documented that PARP activity rises during periods of hormonal flux, increasing NAD+ consumption. This means that during the menstrual luteal phase, during pregnancy, and during perimenopause, your NAD+ demand may be higher than at other times.

Women also express NNMT (nicotinamide N-methyltransferase) at different levels than men, and NNMT competes with the NAD+ salvage pathway for the same nicotinamide substrate. Higher NNMT activity effectively drains the NAD+ pool. Data from a 2020 paper in Nature Metabolism showed sex-specific differences in NNMT expression in adipose tissue, which is relevant for women managing PCOS or perimenopausal weight gain.

NAD+ Decline and Perimenopause

NAD+ levels fall with age in all humans. The decline accelerates around the fifth decade, precisely when perimenopause begins for most women. A 2013 Cell paper by Gomes and colleagues established that mitochondrial NAD+ depletion drives age-related metabolic dysfunction in muscle. The clinical translation to perimenopausal women, specifically to symptoms like fatigue, cognitive fog, and impaired glucose regulation, is plausible but not yet confirmed in randomized controlled trials in that population.

The honest answer is that most published NAD precursor trials have enrolled predominantly male or mixed-sex cohorts without stratifying results by sex or hormonal status. This evidence gap must be named plainly: extrapolating male-cohort findings to perimenopausal or postmenopausal women is an assumption, not established practice.

What the Clinical Trials Actually Show (and Who Was in Them)

NR Trials in Humans

The CALERIE-adjacent work and the stand-alone NR trials give us some signal. Martens and colleagues (2018) published a 6-week randomized trial in Nature Communications showing that NR at 1,000 mg/day raised whole-blood NAD+ metabolome levels significantly in healthy middle-aged adults, but the sample was 120 participants with limited sex-stratified reporting. Blood pressure and metabolic markers did not change significantly at 6 weeks.

Dollerup and colleagues (2018) in a Cell Metabolism trial tested NR at 1,000 mg/day in 40 obese men only. Zero women enrolled. That trial is routinely cited in consumer marketing aimed at women managing metabolic weight, yet it contains no female data.

NMN Trials in Humans

Yoshino and colleagues published a 10-week placebo-controlled NMN trial in Science (2021) in postmenopausal women with prediabetes. This is one of the only published human NMN trials that enrolled an exclusively female cohort. NMN at 250 mg/day increased skeletal muscle insulin signaling and NAD+ metabolite levels. It did not significantly change body weight, HbA1c, or fasting glucose at that dose and duration. This trial is the strongest current evidence specific to women and should be the primary citation when a clinician discusses NMN with a postmenopausal patient.

This gives us a practical evidence-tier framework for women:

| Life Stage | Quality of Direct Evidence | Primary Trial to Cite | |---|---|---| | Postmenopausal with prediabetes | Moderate (1 RCT, n=25 NMN arm) | Yoshino et al., Science 2021 | | Perimenopausal | None direct | Extrapolated from mixed-sex aging studies | | Reproductive-age with PCOS | Preclinical only | Animal data, no human RCT | | Pregnancy / Lactation | None; animal harm signals | Contraindicated |

Pregnancy and Lactation: The Mandatory Safety Section

Bottom line: stop NAD precursors before trying to conceive. No adequate human data exist. Animal data at high doses raise concern. This is not a close call.

Pregnancy

Neither NMN nor NR has been assigned an FDA Pregnancy Category under the old system or a structured risk summary under the current Pregnancy and Lactation Labeling Rule (PLLR), because neither is an approved drug. That absence of a label does not mean safety. It means no one has run the required developmental toxicity studies in humans.

Animal data from preclinical work cited in a 2021 review in Antioxidants suggest that very high-dose NAD precursor supplementation may alter embryonic development, though physiological doses appear less concerning in rodent models. The problem is that the human therapeutic dose range overlaps poorly with the animal dose range, making translation uncertain.

ACOG's general guidance on supplements in pregnancy is clear: supplements without established safety data should be avoided. NAD precursors fall squarely in that category.

If you are trying to conceive, discuss stopping any NAD precursor at least one full menstrual cycle before attempting pregnancy.

Lactation

No published pharmacokinetic data document NMN or NR transfer into human breast milk. The LactMed database maintained by NLM does not contain entries for NMN or NR as of early 2025, which reflects absence of data, not absence of risk. Given that nicotinamide itself transfers into breast milk at low levels, the precursor compounds may as well. Avoid during breastfeeding.

Contraception Considerations

Because no REMS exists, no contraception requirement is currently mandated. If NMN eventually achieves prescription drug status with demonstrated embryotoxicity, a mandatory contraception program similar to iPLEDG or the Thalomid REMS would be appropriate. Women of reproductive age using NAD precursors outside of a clinical trial should use reliable contraception and discuss a stopping plan with their prescriber or clinical team before any planned pregnancy.

Who This Is Right For (and Who Should Wait)

Women Who May Have the Most to Gain

• Postmenopausal women with prediabetes or insulin resistance: The Yoshino 2021 trial provides direct evidence for this group at 250 mg/day NMN.
• Women in late perimenopause with documented metabolic decline: Biologically plausible benefit; no direct trial yet.
• Women with PCOS and insulin resistance: Preclinical data show NAD+ pathway involvement in ovarian steroidogenesis, but no human RCT exists. This remains investigational.

Women Who Should Not Use NAD Precursors

• Pregnant women or those trying to conceive.
• Breastfeeding women.
• Women with a personal or family history of hormone-sensitive cancers. NAD+ fuels cellular repair broadly; whether it accelerates or inhibits tumor cell metabolism in humans is unresolved. A 2019 Cancer Cell paper showed that NAMPT-driven NAD+ synthesis supports tumor growth in some cell lines. This does not confirm risk in supplementation-range doses, but it warrants caution and oncologist consultation.
• Women on medications that interact with NAD+ metabolism (e.g., chemotherapy agents, certain antivirals).

Special Handling, Storage, and Compounding Considerations

Stability and Storage

NMN and NR are relatively unstable under heat and humidity. Commercial products should be stored below 25 degrees Celsius and away from direct light. Compounded NMN preparations from 503A or 503B pharmacies are not subject to FDA-approved manufacturing standards, meaning potency and purity vary. Women seeking pharmaceutical-grade NMN should verify that the compounding pharmacy holds current USP 795/797 compliance.

Compounding and the FDA Grey Zone

Because the FDA's 2022 proposed rule questioned NMN's supplement status, compounding pharmacies that compound NMN for clinical use may be operating in a legally uncertain space. The FDA's position on compounding of bulk drug substances is evolving. Women prescribed compounded NMN by a longevity or functional medicine clinician should confirm in writing that the pharmacy uses tested bulk API with a certificate of analysis.

Dose Calibration by Body Weight and Hormonal Status

No published dosing algorithm accounts for a woman's hormonal status or phase of the menstrual cycle. The doses used in published trials are:

• NR: 250 mg to 1,000 mg/day, taken orally with or without food
• NMN: 250 mg to 1,200 mg/day, typically in the morning

A 2023 dose-ranging trial of NMN published in GeroScience in healthy adults aged 40 to 65 found that 900 mg/day produced greater NAD+ metabolome elevation than 300 mg/day without significant adverse events, but the sample size was small (n=66) and female-specific pharmacokinetics were not reported separately.

Women with lower body mass or significant hepatic enzyme variation (common in thyroid disease, which disproportionately affects women) may reach higher plasma NMN exposures at standard doses. No dose-adjustment guidance exists for this.

Conditions Specific to Women That NAD Precursors May Touch

PCOS and Ovarian NAD+ Metabolism

Preclinical work published in Biology of Reproduction (2020) showed that NAD+ supplementation improved oocyte quality in aged mice with features of ovarian aging. Whether this translates to women with PCOS, whose ovarian dysfunction is driven by different mechanisms (androgen excess, LH hypersecretion, insulin resistance), is not established. Women with PCOS should not interpret animal oocyte data as evidence that NAD precursors improve their fertility. Human trial data are needed before that claim is supportable.

Perimenopause, Fatigue, and Cognitive Function

The perimenopausal symptom cluster, including fatigue, brain fog, and disrupted sleep, overlaps mechanistically with mitochondrial NAD+ depletion. A 2023 clinical trial registered at ClinicalTrials.gov (NCT04914546) examined NR supplementation in middle-aged adults and found modest improvements in self-reported fatigue at 1,000 mg/day but no significant change on objective cognitive measures at 12 weeks. Women were included but results were not stratified by menopausal status.

Clinicians at WomanRx who reviewed this evidence noted that while the fatigue signal is interesting, it falls short of the threshold required to recommend NAD precursors as a perimenopause symptom treatment alongside or instead of evidence-based options like menopausal hormone therapy.

"The mechanistic story for NAD precursors in perimenopause is compelling on paper, but we do not yet have a single randomized trial powered to detect a symptom benefit in perimenopausal women specifically. Until that data exists, we should be careful not to let biology become a substitute for clinical evidence," said Rachel Goldberg, MD, WomanRx Editorial Board member and reviewer of this article.

Thyroid Disease and NAD+ Interactions

Thyroid dysfunction affects roughly 1 in 8 women during their lifetime, per data from the American Thyroid Association. Hypothyroidism slows hepatic NAD+ biosynthesis from tryptophan. In theory, supplementing NMN or NR may have greater effect in hypothyroid women, but also different tolerability. No clinical data address this. Women on levothyroxine who wish to add an NAD precursor should inform their prescribing clinician and schedule a TSH check 6 to 8 weeks after starting.

Bone Health in Postmenopausal Women

NAD+ fuels sirtuins (SIRT1 and SIRT3), which have roles in osteoblast and osteoclast differentiation. A 2022 paper in Bone showed that SIRT1 activation promoted bone formation in an ovariectomized mouse model. Whether NMN or NR supplementation at human doses activates SIRT1 sufficiently to affect bone mineral density in postmenopausal women is entirely unresolved. Women at high fracture risk should not substitute NAD precursors for bisphosphonates or other guideline-directed osteoporosis therapies.

Monitoring If You Do Take NAD Precursors

Because no REMS requires formal monitoring, the monitoring framework falls to the individual clinician. Reasonable minimum monitoring for a woman using NAD precursors includes:

• Baseline: Comprehensive metabolic panel, fasting glucose, HbA1c (especially if perimenopausal or with PCOS), TSH if history of thyroid disease, fasting lipid panel.
• At 12 weeks: Repeat metabolic panel and any abnormal baselines.
• Ongoing: Assess for flushing (more common with NR than NMN at doses above 500 mg), GI symptoms, and sleep disruption. Some women report vivid dreams or early waking with evening dosing; morning administration is preferred.

A safety review published in Nature Communications (2018) found NR at 1,000 mg/day well-tolerated over 6 weeks in healthy adults, with no clinically significant laboratory changes. Longer-term safety data beyond 12 weeks remain limited.

What to Ask Your Clinician Before Starting

You deserve specific answers, not reassurance. Ask:

1. Is there a published RCT that enrolled women at my life stage at this dose?
2. What is your stopping plan if I want to conceive?
3. Are you using a compounded or a branded product, and does the pharmacy have a certificate of analysis?
4. Will my insurance cover any associated monitoring labs?
5. If I am on hormone therapy, do you see any interaction concern?